Hadean Ventures

Hadean Ventures invests in early-stage and growth-stage life sciences companies across the Nordic region and Europe. The firm focuses on therapeutics and medical technology, with initial investments typically ranging from €1 million to €5 million. It maintains a concentrated portfolio of 10–15 companies.

Hadean Ventures primarily targets early-stage companies, including seed and start-up phases, with the capacity to follow on into expansion and late-stage rounds. The firm structures investments as direct equity and occasionally participates in seed rounds alongside other European healthtech investors.

Hadean Ventures covers the Nordic countries and broader European life sciences opportunities. The firm's Oslo headquarters places it within Scandinavia's dense research ecosystem, which includes Karolinska Institute in Sweden and Oslo University Hospital.

The firm sources proprietary deal flow through proximity to Nordic university research ecosystems and hospital clusters. Its in-house scientific team conducts thesis generation and due diligence, which supports a sourcing model built around academic spinouts and pre-institutional life sciences companies.

Hadean Ventures operates as a dedicated life sciences fund manager, not a single-family or multi-family office. Its structure as a specialized asset manager distinguishes it from broader Nordic investment platforms and family offices that allocate across multiple sectors.